TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

University of Alabama at Birmingham, Birmingham

Mayo Clinic Arizona, Scottsdale

University of California San Diego, La Jolla

UCLA Medical Center, Los Angeles

University of California Davis, Sacramento

University of California San Francisco, San Francisco

Colorado Neurological Institute, Englewood

Institute of Neurodegenerative Disorders, New Haven

University of Florida, Gainesville

University of Miami, Miami

University of South Florida, Tampa

Emory University, Atlanta

Medical College of Georgia, Augusta

Rush University Medical Center, Chicago

University of Chicago, Chicago

Indiana University, Indianapolis

University of Iowa, Iowa City

University of Kansas, Kansas City

Hereditary Neurological Disease Centre, Wichita

Johns Hopkins University, Baltimore

Boston University, Boston

Massachusetts General Hospital, Charlestown

University of Michigan, Ann Arbor

Washington University School of Medicine, St Louis

Albany Medical College, Albany

North Shore-LIJ Health System, Manhasset

Columbia University Medical Center, New York

University of Rochester, Rochester

Ohio State University Parkinson's Center, Columbus

Penn State Milton & Hershey Medical College, Hershey

University of Pennsylvania, Philadelphia

University of Pittsburgh, Pittsburgh

University of Tennessee-Memphis, Memphis

Baylor College of Medicine, Houston

University of Virginia, Charlottesville

University of Calgary, Calgary

University of Alberta Glenrose Rehab Hospital, Edmonton

University of British Columbia, Vancouver

University of British Columbia, London

The Centre for Addiction and Mental Health, Markham

Hotel-Dieu Hospital-CHUM, Montreal